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Soluble FAS Ligand: A Discriminating Feature
between Drug-Induced Skin Eruptions and Viral
Exanthemas
Karoline Stur1, Franz M. Karlhofer1 and Georg Stingl1
The clinical spectrum of cutaneous eruptions comprises benign variants like maculopapular rashes (MPRs) and
potentially life-threatening events such as toxic epidermal necrolysis (TEN). Apoptosis of keratinocytes is a
common histopathological feature of all these drug eruptions. As in skin lesions of TEN and Stevens–Johnson
syndrome patients, apoptosis of keratinocytes is often accompanied by an only sparse cellular infiltrate, a
soluble fatty acid synthetase ligand (sFASL)-mediated mechanism of keratinocyte cell death is postulated. In
MPR patients, evidence for the occurrence of a similar process could not be established so far. We therefore
examined sera and lesional skin sections from patients with clinical variants of drug eruptions for FASL
expression using a sandwich ELISA and immunohistochemistry, respectively. As controls, healthy persons and
patients with other inflammatory skin diseases such as viral exanthema were analyzed.Elevated levels of FASL
were detected not only in TEN patients but also in sera and lesional skin of patients with MPR. In contrast, sFASL
was repeatedly negative in all viral exanthemas and healthy controls tested. Thus, determination of sFASL serum
concentration may represent a discriminating tool between drug rashes and viral exanthemas.
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INTRODUCTION
Maculopapular rashes (MPRs) are the most frequently
observed adverse drug-induced skin reactions. They may
develop within days to weeks after initiation of a novel drug
and may last up to 2 weeks after cessation of the culprit
medication. Among the most common drugs responsible are
non-steroidal antirheumatics, anticonvulsants, allopurinol,
and antibiotics such as penicillins, quinolones, and sulfon-
amides (Roujeau et al., 1995; Wolkenstein et al., 1995a, b;
Eliaszewicz et al., 2002). Although drug-induced MPRs are
generally not life-threatening, they considerably diminish the
life quality of patients affected.
Other variants of drug-induced skin diseases are Stevens–-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
(Roujeau and Revuz, 1994; Schwartz, 1997; Becker, 1998),
which are rare but potentially life-threatening (Bastuji-Garin
et al., 1993; Fritsch and Sidoroff, 2000). The evolution of
these clinical conditions is preceded by an, at first, individual
and, late, widespread lethal epidermal injury. The mechan-
ism(s) underlying this phenomenon is (are) not completely
understood. Although it has been originally assumed that
CD8þ cytotoxic T cells are the critical players in this process
(Yawalkar and Pichler, 2001; Pichler, 2002), new data imply
that a humoral pathway, presented by the appearance of fatty
acid synthetase (FAS) and FAS ligand (FASL), is responsible
for keratinocyte death (Tanaka et al., 1996; Viard et al.,
1998). As opposed to the situation seen in healthy skin, FASL
is elevated in sera and abundantly expressed on keratinocytes
of skin sections from TEN patients and, thus, can interact with
FAS (CD95), a death receptor that is constitutively expressed
on the cell surface of keratinocytes. This results in FAS cross-
linking and, subsequently, in rapid apoptosis of keratinocytes
(Abe et al., 2003).
As far as the pathogenesis of ‘‘conventional’’ maculopap-
ular drug eruptions is concerned, the situation is less clear.
Most studies speak in favor of a T-cell-mediated attack
(Yawalkar and Pichler, 2001; Pichler, 2002) and the search
for abnormal FASL has so far yielded negative results in 5/5
patients tested (Viard et al., 1998). For a more thorough
investigation of this issue, we examined sera and skin
sections from 42 patients with MPR as well as patients with
SJS (n¼ 2) and TEN (n¼ 4) for the presence of FASL.
Specimens from 26 patients with various viral exanthemas
and 134 patients with inflammatory skin diseases, all
characterized by keratinocyte injury, served as controls.
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RESULTS
Soluble FASL in drug-induced MPR, erythema multiforme, SJS,
and TEN
Using commercially available ELISA kits (Bender Med
Systems, Vienna, Austria), we explored sera of 42 patients
who had recently developed an MPR owing to the intake of
various drugs. In general, blood samples were obtained on
the day of onset of exanthema and up to 3 days thereafter. In
11 patients analyzed with generalized MPR due to the intake
of b-lactam antibiotics, eight patients (73%) showed in-
creased levels of soluble FASL (sFASL) ranging from 0.34 to
11.36 ng/ml. Similarly, we found elevated titers (1.39 and
2.02 ng/ml) of sFASL in two of five sera (40%) of patients who
had developed an MPR owing to previous non-steroidal anti-
inflammatory drug treatment. In contrast, sFASL was con-
sistently negative in all five sera of patients (100%) with MPR
due to clindamycin (Figure 1).
We also examined the time course of sFASL serum titers in
five patients with cellulitis who had been admitted to our
in-patient ward for intravenous antibiotic treatment. They
newly developed an MPR on average 10 days after b-lactam
antibiotics, had been initiated. Blood samples were obtained
during the first 1–3 days of antibiotic treatment, on the day of
onset of the MPR and on the third day thereafter. All sera
collected on the day of onset of MPR showed highly elevated
concentrations of sFASL (0.67–6.95 ng/ml), whereas sera taken
before the onset of MPR and 3 days thereafter gave negative
results (data not shown).
Elevated levels of sFASL were detected in all three patients
with herpes- triggered erythema multiforme (EM), in both
patients with SJS owing to the intake of quinolones (n¼ 1)
and an unidentified trigger (n¼ 1) and in all four patients with
TEN, which had been induced by the intake of carbamaze-
pine (n¼1) and quinolones (n¼3) (Figure 1). High titers
were observed in sera of SJS with a range from 3.16 to
3.83 ng/ml, whereas levels in patients with EM and TEN
ranged between 0.61 and 0.75 ng/ml and between 0.16 and
0.58ng/ml, respectively (Figure 2).
sFASL in acute viral infections and in other inflammatory
diseases
In all patients with various acute viral infections including
chickenpox, shingles, rubella, fifth disease, and infectious
mononucleosis, serum sFASL levels were negative (Table 1).
In contrast, in two patients with acute infectious mono-
nucleosis infection in whom an MPR had developed owing to
the simultaneous intake of ampicillin, high levels of sFASL
were detected.
Patients with cellulitis (n¼ 45), autoimmune vascular diseases
(lupus erythematosus (n¼ 5) and scleroderma (n¼ 7)), psoriasis
(n¼7), staphylococcal scalded skin syndrome (n¼ 1), para-
neoplastic pemphigus (n¼1), and chronic graft versus host
disease (n¼13) consistently gave negative sFASL results
(o0.1ng/ml). On the other hand, a few patients with atopic
dermatitis (nine of 49; 18%) and acute contact dermatitis (two of
five; 40%) showed positive sFASL concentrations ranging
between 0.65 and 1.89ng/ml (Table 1).
sFASL in healthy controls
The healthy control group represented by 142 blood donors
consistently had negative serum sFASL titers. Thus, the specifi-
city of sFASL in drug-induced skin diseases is 96%, whereas
its sensitivity has a rate of 67%.
FASL expression in regular skin and in skin sections of patients
with various drug reactions or viral exanthema
In our TEN patients, we observed the presence of bound FASL
within all epidermal layers (three of three stained). In
addition, numerous apoptotic keratinocytes were present. In
the biopsy of an EM patient intermediate expression of FASL
within the epidermis was found (one of one stained). In skin
sections of patients with drug-induced MPR, different
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Figure 1. sFASL levels caused by different types of drugs. Highest titers were
measured in patients who received amoxicillin (n¼11). In contrast, patients
with clindamycin treatment (n¼ 5) always showed negative results.
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Figure 2. sFASL levels in patients with EM, SJS, and TEN. Increased sFASL
titers were measured in both SJS patients and the three patients with EM,
whereas sFASL levels were surprisingly low in all four TEN patients.
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amounts of FASL that seem to reflect serum levels of sFASL
were observed. In the epidermis of patients who had received
amoxicillin (two of two stained), or allopurinol (one of one
stained), an increased staining intensity of FASL in suprabasal
and basal layers was apparent. In these sera, sFASL was
elevated. In contrast, FASL expression was only observed on
basal keratinocytes in patients who had developed an MPR
after the intake of clindamycin (three of three stained; Figure
3 c, e, g, i, and k). These patients consistently showed
negative serum titers in sFASL assays. In the skin sections of
the two healthy controls (two of two stained, Figure 3a) and
in the skin section of a patient with rubella, not even traces of
FASL were detected (Figure 3m).
sFAS in study- and comparison group
We observed that sFAS was elevated in all 51 sera (100%)
of the study group with a range from 0.13. to 1.29 ng/ml
(Table 2). Similarly, elevated titers were found in several
diseases of the comparison group including patients with
psoriasis (n¼7; 0.14–1.33 ng/ml), cutaneous lupus erythema-
tosus (n¼ 2; 0.48–0.49ng/ml), and one individual with
paraneoplastic pemphigus (0.67 ng/ml). Furthermore, 14 of
22 patients (64%) with atopic dermatitis (0–1.60 ng/ml), five
of 19 patients (26%) with cellulitis (0–1.25 ng/ml), and three
of four patients (75%) with systemic lupus erythematosus
(0–1.10 ng/ml) presented positive results (Table 3). Eight of 26
patients (31%) with viral exanthemas also showed positive
titers (n¼ 26, 0–0.93ng/ml).
In all healthy controls (n¼ 142), sFAS titers were negative.
Thus, sFAS showed a specificity of 54% and a sensitivity of
100% for drug-induced skin reactions.
FAS expression in skin sections of the study group and
regular skin
FAS expression was positive in all 16 skin sections, which is
in accordance with the reported constitutive presence of FAS
in the regular and diseased epidermis. FAS is constitutively
expressed by keratinocytes throughout the entire epidermis.
The level of expression is not significantly altered in various
skin conditions. Similarly, by immunohistochemistry, we
found comparable levels of FAS expression in the epidermis
of skin biopsies obtained from regular skin and from lesional
skin obtained from patients with MPR, EM, TEN, and rubella
(Figure 3 b, d, f, h, j, l, and n).
DISCUSSION
To determine which inflammatory skin disorders are accom-
panied by serological signs of FAS/FASL overexpression, we
explored 51 sera derived from patients displaying a repre-
sentative spectrum of cutaneous drug eruptions, 160 sera of
individuals with frequent skin diseases routinely seen at our
department, as well as 142 sera of healthy controls.
As opposed to drug rashes (see below), sFASL consistently
gave negative titers in sera of all healthy individuals and,
most notably, of all patients with viral infections such as
chickenpox, shingles, rubella, fifth disease, and infectious
mononucleosis (Table 1). There was also no histopathologic
evidence of FASL expression in the epidermis of such patients
(Figure 3m). The only exception were individuals with an
acute infectious mononucleosis infection and a concurrent
amoxicillin rash (Figure 3). It remains to be determined
whether their highly positive sFASL titers are due to the drug
intolerance and/or the underlying viral infection.
In agreement with other authors investigating this issue,
we found increased serum FASL titers in patients with TEN
and even higher ones in those with SJS (Viard et al.,
1998; Abe et al., 2003). We also detected elevated titers of
sFASL in individuals with herpes simplex-triggered EM
(Figure 2) and, most notably, in the majority of patients with
MPR caused by drugs such as amoxicillin, allopurinol,
anticonvulsants, and quinolones (Figure 1). One explanation
for this discrepancy to the results of Viard et al., 1998 could
be that our study included a larger number of MPR patients
(42 vs 5). Another reason for negative titers could be a delay
of blood sampling and a rapid decline of sFASL levels during
the first few days after onset of the rash. In fact, we and others
(Abe et al., 2003) have observed that serum sFASL levels
decrease significantly between days 3 and 6 after the onset of
disease. We also found that sera of patients with negative
sFASL were frequently those that were collected several days
after the rash had begun. In this regard, it is noteworthy that
our patients with MPR, EM, and SJS displayed titers
consistently higher than those seen in TEN. The likely
explanation for this surprising finding is that our TEN patients
Table 1. Levels of sFASL in diseases of the comparison
group
Diseases Quantity sFASL (ng/ml) %
Acute viral exanthemas
Chickenpox 11 Negative1 0
Shingles 11 Negative 0
Rubella 1 Negative 0
Fifth disease 1 Negative 0
Infectious mononucleosis 2 Negative 0
Inflammatory diseases
Atopic dermatitis 49 0–1.89 18
Contact dermatitis 5 0–1.49 40
Psoriasis 7 Negative 0
Chronic GvHD 13 Negative 0
Cellulitis 45 Negative 0
SSSS 1 Negative 0
Autoimmune diseases
CCLE 2 Negative 0
SLE 4 Negative 0
Scleroderma 7 Negative 0
Paraneoplastic pemphigus 1 Negative 0
CCLE, chronic cutaneous lupus erythematosus; GvHD, graft-versus-host
disease; sFASL, soluble fatty acid synthetase ligand; SLE, systemic lupus
erythematosus; SSSS, staphylococcal scalded skin syndrome.
1Titer o0.1 ng/ml.
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had already been treated for several days at other hospitals
where blood samples were not collected and FASL titers
had perhaps declined. All TEN/SJS patients received high-
dose corticosteroid therapy followed by intravenous immuno-
globulins therapy (with doses ranging from 0.2 to 0.75 g/kg of
body weight per day for four consecutive days) in the case of
TEN. It would be interesting to determine whether these drugs
can adversely affect the activity of FASL. One can also not
exclude the possibility that low FASL serum levels in TEN
patients may have resulted, at least partly, from a preferential
accumulation and a defective release of FASL in/from the
lethally damaged epidermis.
Histopathologically, drug-induced MPR are characterized
by a vacuolar interface dermatitis with predominant T-cell
infiltration (Pichler, 2002). Mechanisms underlying this
phenomenon have not been entirely clarified. In certain
patients, T-cell cytotoxicity involving perforin and granzyme
B is apparently operative (Yawalkar and Pichler, 2001). Our
study strongly suggests that a FAS/FASL-dependent apoptotic
pathway can also be involved in the pathogenesis of MPRs.
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Figure 3. Immunohistochemical staining. Immunohistochemical staining for FAS and FASL in (a and b) regular skin and skin sections of (c and d) TEN,
(e and f) EM, and (g, h, i, j, k, and l) MPR patients. Representative examples were stained with either the rat anti-mouse FASL antibody A11 or the mouse
anti-human FAS antibody UB2 and antibody binding was visualized as described in Materials and Methods. (b, d, f, h, j, l, and n) FAS expression in regular skin
and in skin of patients with MPR, EM, TEN, and viral exanthema (rubella) was observed throughout in the entire epidermis. (a) FASL was not detectable in
regular skin. (c) The skin of a TEN patient showed large amounts of FASL expression in all epidermal layers with numerous apoptotic keratinocytes. Intermediate
FASL expression was observed (e) in the skin of a patient with EM, as well as (g) in the skin section of a patient with MPR owing to the intake of allopurinol
and (i) in another patient with MPR induced by amoxicillin treatment. The skin section of an MPR patient under clindamycin therapy (k) provided FASL
expression in the basal keratinocytes layer only. Comparable FASL expression on basal keratinocytes was observed in other inflammatory skin diseases
(e.g., atopic dermatitis) with negative sFASL serum titers (data not shown). (m) No traces of FASL were found in the skin section of a patient with rubella.
Bar¼50 mm.
Table 2. Levels of sFAS in patients of the study group
Disease sFAS (ng/ml)
MPR (42) 0.36–1.19
EM (3) 0.13–0.32
SJS (2) 0.39–1.29
TEN (4) 0.52–0.92
EM, erythema multiforme; MPR, maculopapular rash; sFAS, soluble fatty
acid synthetase; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal
necrolysis.
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This may also occur in a T-cell-independent manner, that is,
by mere contact of keratinocytes expressing both, FAS and
FASL, on their surfaces. On the basis of our immunhisto-
chemical studies, we believe that keratinocytes rather than
other intra- or even extracutaneous cell types (Liles et al.,
1996; Pinkoski et al., 2000; Abe et al., 2003) are the main
source of FASL. From what is known about its biology, we
would assume that the form of FASL detected within the
cytoplasm of keratinocytes of MPR/SJS/TEN biopsies is bio-
logically inactive (Viard-Leveugle et al., 2003). The alter-
native possibility that keratinocyte-derived, biologically
active sFASL would be re-engulfed by viable keratinocytes
cannot be formally excluded but is quite unlikely.
Our observation of high FASL expression in the skin of
patients with allopurinol-induced rashes as opposed to its
absence in clindamycin recipients may indicate that the
structural features of the drug determine which MPR-inducing
cellular pathway is chosen.
Notably, we also detected increased FASL serum titers in a
few patients with atopic dermatitis (nine of 49; 18%) and
acute contact dermatitis (two of five; 40%) (Table 1). This is in
agreement with the studies by Trautmann et al. (2000,
2001a, b) who described keratinocyte apoptosis in eczema-
tous dermatitis induced by activated T cells releasing sFASL
and interferon-g which, by itself, induces FAS expression on
keratinocytes.
Apart from these theoretical considerations concerning the
pathogenesis of drug rashes, our results demonstrate that the
determination of FASL serum levels can be a most valuable
tool to discriminate drug-induced skin reactions from other
clinically resembling skin diseases such as exanthe-
matous viral infections and may thus find wide clinical
application.
MATERIALS AND METHODS
Patients
We analyzed three different groups of individuals, that is (a) the main
study group (n¼ 51; 28 female, 23 male) consisting of 42 patients
with a generalized MPR, three patients with herpes-simplex-
triggered EM (with less than 10% of body surface involvement, with
sparing of the mucous membranes, a typical histopathology of EM,
and characteristic iris lesions on the distal extremities), two patients
with SJS (with mucosal erosions, widespread purpuric macules, flat
atypical targets, and epidermal detachment below 10% of body
surface area), and four patients with TEN (with severe mucous
membrane involvement, large bullae, full thickness epidermal loss
over 30% of total body area, and a generalized positive Nikolsky’s
sign); (b) a comparison group (n¼ 160; 83 female, 77 male) with 26
viral exanthemas and 134 patients with other inflammatory diseases
(Table 1); (c) a healthy control group (n¼ 142). The age of the
patients ranged between 12 and 94 years. The study was performed
in full compliance with the Declaration of Helsinki Principles. An
approval by the ethics committee was not required for this study.
Biopsies and blood samples were routinely taken from every patient
for diagnostic purposes, followed by an informed consent about a
possible scientific use of the data obtained.
Serum and skin samples
Serum and skin samples were obtained from patients who were seen
and treated at our department between April 2002 and July 2004.
Skin biopsy specimens were taken from non-sun-exposed areas
under local anesthesia with 2% scandicain and processed for routine
histologic and immunomorphologic examinations. Blood was
usually obtained during the first 3 days after admission. In certain
instances, blood samples were collected up to 7 days thereafter.
Serum was obtained by centrifugation of whole blood at 2,500 r.p.m.
for 10 minutes at room temperature, aliquoted, and stored at 201C
until the day of the assay. Sera were analyzed immediately after
thawing as a rapid decline of activity was noticed with certain assays
(sFASL).
Immunohistochemistry
Punch biopsies from affected and healthy skin were embedded in
OCT (Miles, Elkhart, IN) and frozen in liquid nitrogen-cooled
isopentane. Five-micrometer thick sections were cut and allowed
to dry for 2 hours before fixation in acetone at 201C for 10 minutes.
The cryostat sections were treated with either a rat anti-mouse FASL
antibody (A11, the mAb, which when raised against murine
FASL, shows cross-reactivity with human FASL as clearly demon-
strated by Saas et al. (1997)) Alexis Corp., San Diego, CA) or a
mouse anti-human FAS antibody (UB2, Beckman Coulter Interna-
tional SA, Nyon, Switzerland) and stained using the Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA), a procedure for
localizing specific antigens using a biotinylated rabbit anti-rat
antibody or a biotinylated horse anti-mouse antibody and a
horseradish peroxidase avidin D complex (in preliminary staining
experiments, we also used two other anti-FASL antibodies, that is,
the mouse anti-human FASL mAb NOK-1 (BD Pharmingen, San
Diego, CA) and the polyclonal rabbit anti-FASL antibody N20 (Santa
Cruz Biotechnology Inc., Santa Cruz, CA). Both antibodies yielded
the same results as A11 but NOK-1 staining intensity was
comparatively weaker and that of N20 resulted in a stronger
background).
Subsequently, the staining reaction was developed with 3-amino-
9-ethylcarbazole, and hematoxylin was used for counterstaining.
Isotype controls for FAS (mouse IgG1, Immunotech) and FASL
(rat IgM, Immunotech) were performed for each skin section
examined.
Table 3. Levels of sFAS in patients of the comparison
and control group
Disease sFAS (ng/ml)
Atopic dermatitis (22) 0–1.60
Cellulitis (19) 0–1.25
Cutaneous lupus erythematosus (2) 0.48–0.49
SLE (4) 0–1.10
Psoriasis (7) 0.14–1.33
Paraneoplastic pemphigus (1) 0.67
Viral exanthemas (26) 0–0.93
Healthy controls (142) Negative
sFAS, soluble fatty acid synthetase; SLE, systemic lupus erythematosus.
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ELISA
For the investigation of sFAS and sFASL, we used commercially
available sandwich ELISA kits purchased from Bender MedSystems
(Vienna, Austria, Europe).
A mAb, directed against the particular antigens, is adsorbed onto
the bottom of 96 wells of a microwell plate in which 100 ml per well
of six different standards and 100 ml per well serum samples are
assayed in duplicate. In the first step, the adsorbed antibody binds to
the particular antigen present in the standards and samples. Then
50 ml of a biotin-conjugated antibody is added, which also binds
to the antigen captured by the first antibody. Two hours after the
first incubation at room temperature, unbound biotin-conjugated
antibody is removed by washing with buffer, thereafter, 100 ml of
streptavidin-horseradish peroxidase is added. After 1 hour of second
incubation, unbound streptavidin-horseradish peroxidase is removed
by washing. Next, 100 ml of substrate solution reactive with
horseradish peroxidase is added to the wells. After 10 minutes of
incubation, 100 ml of stop solution is added to finish the enzyme
reaction and the results are taken by reading the absorbance on a
spectrophotometer using 450 nm as the primary wave length. The
limit of detection was 0.16 ng/ml.
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